Kallyope

📍 New York, United States🗓 Founded 2015👥 84 employees💰 Last funded Feb 2022
Biotechnology Research🌐 kallyope.com
Website LinkedIn
At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.
4
Total investors
2
Early stage
0
Mid stage
2
Late stage
2015
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2015–2022 · investors recorded per year
201512017120222
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Kallyope?
Kallyope has 4 investors on record on gritt.io, including 2 early-stage backers and 2 late-stage investors.
When did Kallyope last raise funding?
The most recent investment in Kallyope recorded on gritt.io was in February 2022.
When was Kallyope founded?
Kallyope was founded in 2015.
What industry is Kallyope in?
Kallyope operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Kallyope based?
Kallyope is headquartered in New York, United States.